Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 207970
Company: ACTAVIS
Company: ACTAVIS
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| CABAZITAXEL | CABAZITAXEL | 60MG/6ML (10MG/ML) | SOLUTION;INTRAVENOUS | Prescription | None | Yes | Yes |
| CABAZITAXEL INJECTION | CABAZITAXEL | 60MG/6ML | INJECTABLE;INJECTION | None (Tentative Approval) | None | No | No |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 03/14/2024 | ORIG-1 | Approval | Type 5 - New Formulation or New Manufacturer | STANDARD |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/207970s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/207970Orig1s000ltr.pdf |
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
|---|---|---|---|---|---|
| 03/14/2024 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/207970s000lbl.pdf |